Bouchet C - Search Results

1

[Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].

Bouchet C, Hacène K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Bouchet C, et al. Pathol Biol (Paris). 2000 Nov;48(9):825-31. Pathol Biol (Paris). 2000. PMID: 11141918 French.

2

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

Foucré D, Bouchet C, Hacène K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A, Oglobine J. Foucré D, et al. Among authors: bouchet c. Br J Cancer. 1991 Nov;64(5):926-32. doi: 10.1038/bjc.1991.428. Br J Cancer. 1991. PMID: 1931618 Free PMC article.

3

[Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].

Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Bouchet C, et al. Bull Cancer. 1994 Sep;81(9):770-9. Bull Cancer. 1994. PMID: 7703566 French.

4

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Bouchet C, et al. Br J Cancer. 1994 Feb;69(2):398-405. doi: 10.1038/bjc.1994.74. Br J Cancer. 1994. PMID: 8297742 Free PMC article.

5

Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

Bouchet C, Spyratos F, Hacène K, Durcos L, Bécette V, Oglobine J. Bouchet C, et al. Br J Cancer. 1998 May;77(9):1495-501. doi: 10.1038/bjc.1998.246. Br J Cancer. 1998. PMID: 9652768 Free PMC article.

6

Dissemination risk index based on plasminogen activator system components in primary breast cancer.

Bouchet C, Hacène K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Bouchet C, et al. J Clin Oncol. 1999 Oct;17(10):3048-57. doi: 10.1200/JCO.1999.17.10.3048. J Clin Oncol. 1999. PMID: 10506599

7

Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.

Ferrero-Poüs M, Hacène K, Bouchet C, Le Doussal V, Tubiana-Hulin M, Spyratos F. Ferrero-Poüs M, et al. Among authors: bouchet c. Clin Cancer Res. 2000 Dec;6(12):4745-54. Clin Cancer Res. 2000. PMID: 11156229

8

Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.

Bouchet C, Ferrero-Poüs M, Hacène K, Becette V, Spyratos F. Bouchet C, et al. Int J Biol Markers. 2003 Jul-Sep;18(3):207-17. doi: 10.1177/172460080301800309. Int J Biol Markers. 2003. PMID: 14535592 Free article.

9

Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer.

Spyratos F, Bouchet C, Tozlu S, Labroquere M, Vignaud S, Becette V, Lidereau R, Bieche I. Spyratos F, et al. Among authors: bouchet c. Anticancer Res. 2002 Sep-Oct;22(5):2997-3003. Anticancer Res. 2002. PMID: 12530032

10

Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.

Romain S, Spyratos F, Lainé-Bidron C, Bouchet C, Guirou O, Martin PM, Oglobine J, Magdelénat H. Romain S, et al. Among authors: bouchet c. Eur J Clin Chem Clin Biochem. 1995 Sep;33(9):603-8. Eur J Clin Chem Clin Biochem. 1995. PMID: 8611670

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters